Search for Brian Nichol's latest article with this title. Didn't make the headlines it seems, but a nice mention of NBS.
"Currently, there are two companies, Baxter (BAX) and NeoStem (NBS), with late-stage clinical products (essentially the same products), which are being used to treat different conditions of the heart. With 600,000 people who die every year in the U.S. alone from heart disease, any treatment that can strengthen or repair the heart would be a blockbuster due to the pure size of the market. Hence, with both companies producing exceptional clinical results - with different approaches - I think the development of CD34+ cells could very well be the next biotech area of development to produce large gains."